Cere­nion strength­ens brain mon­i­tor­ing inno­va­tion with new US patent

Cere­nion has been grant­ed a US patent for inno­v­a­tive sig­nal pro­cess­ing tech­nol­o­gy designed to sup­port reli­able EEG analy­sis in chal­leng­ing clin­i­cal con­di­tions. The patent strength­ens the company’s intel­lec­tu­al prop­er­ty port­fo­lio and sup­ports its plans for enter­ing the US mar­ket.

Con­tin­u­ous EEG mon­i­tor­ing in acute health­care comes with real-world chal­lenges. Inter­rup­tions in record­ings can affect the qual­i­ty of data used for analy­sis. Cerenion’s patent­ed method address­es miss­ing or cor­rupt­ed EEG data by gen­er­at­ing replace­ment sig­nal seg­ments that pre­serve rel­e­vant char­ac­ter­is­tics of the orig­i­nal record­ing, sup­port­ing more con­sis­tent quan­ti­ta­tive EEG analy­sis.

“Secur­ing this patent is an impor­tant mile­stone for Cere­nion and a recog­ni­tion of the inno­v­a­tive work of our team,” says Dr. Juk­ka Kor­te­lainen, CEO and co-founder of Cere­nion. “Our mis­sion is to make EEG mon­i­tor­ing in acute health­care eas­i­er and more acces­si­ble. Pro­tect­ing our inno­va­tions in the US sup­ports this ambi­tion and our long-term plans for the mar­ket.”

The patent reflects Cerenion’s com­mit­ment to devel­op­ing prac­ti­cal solu­tions for the chal­lenges of brain mon­i­tor­ing in acute health­care, with the ulti­mate goal of sup­port­ing bet­ter care for crit­i­cal­ly ill patients.

Source 8text and image): Cere­nion